raxibacumab
AssetAlso called Abthrax
Binds anthrax protective antigen, blocking toxin entry into host cells.
- Stage
- Approved
- Modality
- Antibody
- Target
- PRDX1
- 3
- Indications
- 3
- Trials
- 2
- Developers
Approved by the FDA on Dec 14, 2012 (BLA125349). FDA
Indications
3Anthrax
Approved, FDA
Bacterial infection
Phase 3, Completed, NCT02339155, clinicaltrials.gov, Nov 12, 2026
Therapeutic treatment of inhalation anthrax
Phase 2, Completed, NCT02016963, clinicaltrials.gov, Nov 12, 2026
In the full profile
- Target and mechanism1
- Owner and partners2
- Trials3
- Evidence for its targets1
Every asset’s record: target, stage, trials and the evidence behind it.